Forti G, Krausz C
Department of Clinical Physiopathology, University of Florence, Italy.
J Clin Endocrinol Metab. 1998 Dec;83(12):4177-88. doi: 10.1210/jcem.83.12.5296.
Infertility by itself does not threaten physical health but has a strong impact on the psychological and social well-being of couples. In the last two decades, progress in caring for the infertile couple, in particular progress in the field of assisted reproduction and micromanipulation, has provided significant hope for many couples for whom hope could not have been offered in the past. This is especially true for bilateral tubal disease and for male factor infertility, as nearly all couples with male factor infertility can now undergo either one (or more) IVF or ICSI attempt(s). For couples with other causes of infertility, however, the differences in pregnancy rates often do not reach statistical significance. We must also remember that the total cost incurred for successful delivery for couples with a better chance of successful IVF (i.e. those with tubal disease) increases from approximately $55,000 in American dollars for the first cycle to $73,000 by the sixth cycle. Because of these high costs, many insurers in the United States and many public health systems in Europe do not cover or only partially cover these procedures. Consequently, the availability of IVF and related therapies frequently depends on the couple's ability to pay. Therefore, after having established the correct diagnosis, appropriate treatment should be counseled to the infertile couple keeping in mind the following points: 1) in subfertile couples expectant management should be reasonably counselled if the age of the woman is less than 30 yr and the duration of infertility is less than 36 months, even if oligozoospermia is present; 2) superovulation and timed intercourse seems also to be a reasonable approach in couples with anovulatory, mild/moderate endometriosis, and unexplained infertility; 3) in unexplained infertility, ovarian stimulation (with clomiphene or gonadotropin) and IUI seem to offer some advantage over ovarian stimulation and timed intercourse; 4) IVF can be a firstline approach in tubal sterility and when IUI or IPI cannot be performed because the number of motile sperm is insufficient, but is usually also the final treatment attempt when other methods have failed. The outcome of IVF is negatively influenced mainly by the woman's age; however, the number of deliveries is also generally lower in couples with male factor; 5) ICSI is a further option, which should be limited to couples: a) with very poor semen parameters; b) previous failed fertilization; c) presence of obstructive or nonobstructive azoospermia in which ICSI is combined with sperm extraction from the epididymis or the testis; 6) international register studies demonstrate that the risk of malformation after conventional IVF is not increased; 7) some reports suggest that incidence of congenital major and minor malformations is not increased in children born after ICSI. However, the rate of sex chromosome anomalies in ICSI fetuses has been reported to be approximately 1% in 585 prenatal diagnoses, a frequency increased by a factor of 4 if compared with naturally conceived live-born babies. ICSI bypasses the physiological selection of spermatozoa that occurs at the level of the testis and epididymis, and in the female reproductive tract as well as at the sperm-oocyte interface. As genetic abnormalities are present in a significant percentage of infertile males with impaired spermatogenesis, karyotyping and analysis of the Y chromosome for microdeletions should be carried out in all potential ICSI fathers. Screening for cystic fibrosis gene mutations should also be performed in azoospermia caused by congenital absence of the vas deferens and seminal vesicles. Appropriate genetic counseling should be made available to all ICSI couples whenever a gene or chromosomal anomaly has been identified. With most ARTs the average delivery rate per cycle is approximately 15% and the cumulative delivery rate after several cycles is about 50%. (ABSTRACT TRUNCATED)
不孕本身不会威胁身体健康,但会对夫妻的心理和社会幸福感产生强烈影响。在过去二十年中,在照顾不孕夫妇方面取得了进展,特别是在辅助生殖和显微操作领域的进展,为许多过去无法获得希望的夫妇带来了巨大希望。对于双侧输卵管疾病和男性因素不孕尤其如此,因为现在几乎所有男性因素不孕的夫妇都可以进行一次(或多次)体外受精(IVF)或卵胞浆内单精子注射(ICSI)尝试。然而,对于其他不孕原因的夫妇,妊娠率的差异往往没有达到统计学显著性。我们还必须记住,对于体外受精成功几率较高的夫妇(即输卵管疾病患者),成功分娩的总费用从第一个周期的约55,000美元增加到第六个周期的73,000美元。由于这些高昂的费用,美国的许多保险公司和欧洲的许多公共卫生系统不涵盖或仅部分涵盖这些程序。因此,体外受精及相关治疗的可及性往往取决于夫妇的支付能力。因此,在确立正确诊断后,应向不孕夫妇提供适当的治疗建议,同时牢记以下几点:1)对于不育夫妇,如果女性年龄小于30岁且不孕时间小于36个月,即使存在少精子症,也应合理建议期待管理;2)对于无排卵、轻度/中度子宫内膜异位症和不明原因不孕的夫妇,超排卵和定时性交似乎也是一种合理的方法;3)对于不明原因不孕夫妇,卵巢刺激(使用克罗米芬或促性腺激素)和宫腔内人工授精(IUI)似乎比卵巢刺激和定时性交更具优势;4)体外受精可以作为输卵管性不孕的一线方法,以及当由于活动精子数量不足而无法进行宫腔内人工授精或宫腔内配子移植(IPI)时的方法,但通常也是其他方法失败后的最终治疗尝试。体外受精的结果主要受到女性年龄的负面影响;然而,男性因素夫妇的分娩数量通常也较低;5)卵胞浆内单精子注射是另一种选择,应限于以下夫妇:a)精液参数非常差;b)先前受精失败;c)存在梗阻性或非梗阻性无精子症,其中卵胞浆内单精子注射与从附睾或睾丸提取精子相结合;6)国际登记研究表明,传统体外受精后畸形风险没有增加;7)一些报告表明,卵胞浆内单精子注射后出生的儿童先天性主要和次要畸形的发生率没有增加。然而,据报道,在585例产前诊断中,卵胞浆内单精子注射胎儿的性染色体异常率约为1%,与自然受孕的活产婴儿相比,该频率增加了4倍。卵胞浆内单精子注射绕过了在睾丸和附睾水平、女性生殖道以及精子-卵母细胞界面发生的精子生理选择。由于在相当比例的精子发生受损的不育男性中存在遗传异常,所有潜在的卵胞浆内单精子注射父亲都应进行染色体核型分析和Y染色体微缺失分析。对于先天性输精管和精囊缺如导致的无精子症患者,还应进行囊性纤维化基因突变筛查。每当识别出基因或染色体异常时,都应为所有卵胞浆内单精子注射夫妇提供适当的遗传咨询。对于大多数辅助生殖技术,每个周期的平均分娩率约为15%,几个周期后的累积分娩率约为50%。(摘要截选)